Plain English Summary
Background and study aims
Obstructive sleep apnea (OSA) is a breathing condition with an increased cardiovascular (heart disease) risk. especially those with moderate-severe OSA. Recent publications describe different subtypes of patients at the same OSA severity. In this setting, the presence of OSA and cardiovascular disease could define a potentially different phenotype with an increased risk of cardiovascular mortality. Other phenotypes are related to a different profile of patients according to a symptom-based approach, these patients report excessive sleepiness, snoring and high Epworth sleepiness scale. This subtype was independently associated with increased mortality risk. However, the prevalence of cardiovascular comorbidities and OSA subtypes in the Latino/Hispanic population is unclear. The aim of this study is to describe different subtypes of moderate-severe OSA in Chilean patients and to explore the association between these subtypes and cardiovascular comorbidities.
Who can participate?
Patients over the age of 18 referred for the sleep study because of the clinical suspicion of OSA (snoring symptoms, apneas observed by bed partner or excessive daytime sleepiness or major cardiovascular comorbidities)
What does the study involve?
The study includes participants with a recent diagnosis of moderate-severe OSA after a home sleep apnea test. Patients with mild and no OSA are defined as the control group. The aim is to define potential subtypes of patients using symptoms-based, oximetric-based and clinical-based approaches. The researchers also plan to describe different profiles of patients with moderate-severe OSA in Chile such as the elderly population, the female population, among others. Finally, the study explores the association between different oximeter measures reported in HSAT and cardiovascular outcomes, including mortality.
What are the possible benefits and risks of participating?
There will be no immediate direct benefit to those taking part. Participants will receive the usual care.
Where is the study run from?
Clínica Las Condes, Santiago (Chile)
When is the study starting and how long is it expected to run for?
June 2009 to June 2025
Who is funding the study?
Investigator initiated and funded
Who is the main contact?
1. Jorge Jorquera, MD
jjorquera@clinicalascondes.cl
2. Gonzalo Labarca, MD FACP
glabarcat@gmail.com
Trial website
Contact information
Type
Public
Primary contact
Dr Jorge Jorquera
ORCID ID
http://orcid.org/0000-0003-4348-8678
Contact details
Estoril
450. Las Condes. RM.
Santiago
7591047
Chile
+56 (0)992896812
jjorquera@clinicalascondes.cl
Type
Scientific
Additional contact
Dr Gonzalo Labarca
ORCID ID
http://orcid.org/0000-0002-0069-3420
Contact details
Via del Rio
3825. Chiguayante
Concepcion
4100122
Chile
+56 (0)978787484
glabarcat@gmail.com
Additional identifiers
EudraCT number
Nil known
ClinicalTrials.gov number
Nil known
Protocol/serial number
E012018
Study information
Scientific title
Prevalence of cardiovascular comorbidities and association with different subtypes of Chilean patients with moderate-severe Obstructive Sleep Apnea in Santiago (SantOSA)
Acronym
SantOSA
Study hypothesis
The researchers hypothesise that in Chilean patients with moderate-severe OSA, patients report different subtypes (phenotypes) according to clinical manifestations commonly found at sleep clinics and this association may be linked to an increased cardiovascular risk.
Ethics approval
Approved January 2018, Ethics Committee of the Institution the Institution Review Board (Clinica Las Condes, Estoril 450, Las Condes, Santiago, Chile, ZIP: 7591047; Tel: +56 (0)226103279; Email: cetica-secre@clinicalascondes.cl), IRB: 00008758
Study design
Prospective cohort study
Primary study design
Observational
Secondary study design
Cohort study
Trial setting
Hospitals
Trial type
Diagnostic
Patient information sheet
Condition
Obstructive sleep apnea
Intervention
The researchers developed a prospective cohort study of participants aged > 18 years since 2009 who were prospectively included to date in a single tertiary center. They will include all participants who were referred for the sleep study who performed an ambulatory home sleep apnea test (HSAT) because of the clinical suspicion of OSA (snoring symptoms, apneas observed by bed partner or excessive daytime sleepiness or major cardiovascular comorbidities).
Prior to the HSAT, a clinical examination and symptom standardized questionnaire was applied with the purpose of evaluating their sleep schedule, degree of daytime sleepiness, snoring, apnea observed by a bed partner, insomnia, episodes of nocturnal suffocation, and morning headache in addition to ESS. The study will include sociodemographic data, information about habits (tobacco and alcohol use), and anthropometric data (such as weight, height, body mass index (BMI) and neck circumference) were also recorded. The study also included the Flemons predictive model score (adjusted by neck circumference), nasal obstruction symptoms evaluation (NOSE), STOP-BANG and comorbidity characteristics at baseline (diagnosis of hypertension, T2DM, CHD, DLP, and stroke) and depression will be evaluated using the BECK questionnaire.
The researchers standardized the HSAT using an Embletta MPR equipment ([Embla Systems, USA) following the current recommendations and requirements of scientific societies for level III studies by American Society of Sleep Medicine (ASSM). OSA diagnosis requires an apnea-hypopnea index > 5 ev/hr, between 5-15 ev/hr is mild OSA and moderate-severe OSA requires an AHI > 15 ev/hr.
The plan is to categorize the data according to sleep apnea test results in two groups of analysis: the study group (moderate-severe OSA) and the control group (no OSA – mild OSA), for the control group, patients with other sleep apnea disorders after sleep study (including polysomnogram) study.
For a comprehensive analysis of different subtypes of patients, the researchers will explore different clinical subtypes through cluster analysis. For this purpose, they plan to develop a Latent class analysis, using a two-step auto-clustering process, and the number of clusters with the lowest Bayesian information will be selected as the number of clusters for further analysis. They plan to perform a sensitive analysis in order to define potentially subtype using: 1) a symptoms-based approach, 2) an oximetric-based approach and 3) a clinical-based approach.
The researchers also plan to perform a description of different profile of patients with moderate-severe OSA in Chile such as elderly population, female population, among others. Finally, they will explore the association between different oximeter measures reported in HSAT and cardiovascular outcomes, including mortality.
Intervention type
Other
Phase
Drug names
Primary outcome measure
1. All-cause mortality measured through a review of the national register database (www.registrocivil.cl) at 3, 5 and 10 years
2. Cardiovascular mortality measured through a review of the national register database (www.registrocivil.cl) at 3, 5 and 10 years
Secondary outcome measures
1. New onset of hypertension measured by either medical record or telephone consultation at 5 and 10 years
2. New onset of T2DM measured by either medical record or telephone consultation at 5 and 10 years
3. New onset of CHD measured by either medical record or telephone consultation at 5 and 10 years
4. New onset of atrial fibrillation measured by either medical record or telephone consultation at 5 and 10 years
Overall trial start date
01/06/2009
Overall trial end date
31/12/2035
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Participants aged > 18 years
2. Referred for the sleep study because of the clinical suspicion of OSA (snoring symptoms, apneas observed by bed partner or excessive daytime sleepiness or major cardiovascular comorbidities)
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
3000 participants
Participant exclusion criteria
1. Participants with other sleep disorders such as periodic limb movements of sleep (PLMS), NREM and arousal, REM and hypoxia, arousal and poor sleep
2. Participants who refuse to sign the consent form
Recruitment start date
01/08/2009
Recruitment end date
31/12/2025
Locations
Countries of recruitment
Chile
Trial participating centre
Clinica Las Condes
Estoril 450, Las Condes, Región Metropolitana
Santiago
7591047
Chile
Sponsor information
Organisation
Clinica Las Condes
Sponsor details
Estoril 405
Las Condes
Santiago
7591047
Chile
+56 (0)2 2210 4000
mgalvez@clinicalascondes.cl
Sponsor type
Hospital/treatment centre
Website
Funders
Funder type
Other
Funder name
Investigator initiated and funded
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
The researchers plan to publish their results after a peer-review process. The results will provide information for future studies that clinicians could use to make patient-centred decisions and that healthcare managers, administrator and policymaker could use to guide allocation.
IPD sharing statement
The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.
Intention to publish date
01/10/2019
Participant level data
Other
Basic results (scientific)
Publication list